4月1日にNuvalenCFOは 株式を120万ドルで売った. Nuvalent CFO sold $1.2M in stock on April 1.

ニューヴァレント (NASDAQ: NUVL) は,その財務責任者が4月1日に約120万ドルの株式を売却し,彼の株価はほぼ12%減少したと報告した. Nuvalent (NASDAQ: NUVL) reported that its Chief Financial Officer sold approximately $1.2 million in stock on April 1, reducing his stake by nearly 12%. 臨床段階の腫瘍学会社は 金曜日に105.43ドル近くで取引され,高額だった. The clinical-stage oncology company saw its shares trade near $105.43 on Friday with high volume. アナリストは"中等な買い物"のコンセンサス評価を137.25ドルの目標価格で持っていますが,一部の企業は"売り"の格付けを与えています. Analysts have a "Moderate Buy" consensus rating with a target price of $137.25, though some firms have assigned a "sell" rating.